Human mortalin (HSPA9):: a candidate for the myeloid leukemia tumor suppressor gene on 5q31

被引:24
|
作者
Xie, H
Hu, Z
Chyna, B
Horrigan, SK
Westbrook, CA
机构
[1] Univ Illinois, Dept Med, Sect Hematol Oncol, Chicago, IL 60607 USA
[2] Georgetown Univ, Dept Pediat, Washington, DC 20057 USA
关键词
mortalin; HSPA9; genomic structure; mutation; tumor suppressor;
D O I
10.1038/sj.leu.2401935
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Human mortalin (HSPA9) was originally identified by its close homology to murine mortalins, which play important roles in cellular senescence. The two murine genes, mot-1 and mot-2, differ in only two amino acid residues, but have opposite functions in cellular immortalization. HSPAS was recently localized to chromosome 5, band q31, a region that is frequently deleted in myeloid leukemias and myelodysplasia (MDS), making it a candidate tumor suppressor gene, which is consistent with the biological function of its murine homologue. To evaluate mortalin in this capacity, its expression in normal and leukemic cell lines was investigated, and its genomic structure was determined in order to facilitate mutation detection. RT-PCR and Northern blot analysis revealed a broad distribution in normal tissues and in leukemia cell lines, producing a single 2.8 kb transcript. Genomic characterization showed that the gene spans 18 kb, and consisted of 17 exons with boundaries that were almost identical to its murine counterpart. Using Intron-based primers to flank each exon, sequence of the complete protein-coding regions was obtained for three AML cell lines, including two lines with chromosome 5 loss (KG-1 and HL-60) and one without (AML-193) compared to normal DNA. No mutations were identified although one conservative nucleotide sequence variant was observed in exon 16. We have shown that mortalin is highly conserved in genomic structure as well as sequence, and the designed primers will be suitable for future studies to detect mutations In clinical samples.
引用
收藏
页码:2128 / 2134
页数:7
相关论文
共 50 条
  • [31] Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemia
    Oing, Christoph
    Jost, Edgar
    Dahl, Edgar
    Wilop, Stefan
    Osieka, Rainhardt
    Bruemmendorf, Tim H.
    Galm, Oliver
    CANCER RESEARCH, 2011, 71
  • [32] Frequent Long-Range Epigenetic Silencing of Protocadherin Gene Clusters on Chromosome 5q31 in Wilms' Tumor
    Dallosso, Anthony R.
    Hancock, Anne L.
    Szemes, Marianna
    Moorwood, Kim
    Chilukamarri, Laxmi
    Tsai, Hsin-Hao
    Sarkar, Abby
    Barasch, Jonathan
    Vuononvirta, Raisa
    Jones, Chris
    Pritchard-Jones, Kathy
    Royer-Pokora, Brigitte
    Lee, Sean Bong
    Owen, Ceris
    Malik, Sally
    Feng, Yi
    Frank, Marcus
    Ward, Andrew
    Brown, Keith W.
    Malik, Karim
    PLOS GENETICS, 2009, 5 (11)
  • [33] Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31
    Simoneau, M
    Aboulkassim, TO
    LaRue, H
    Rousseau, F
    Fradet, Y
    ONCOGENE, 1999, 18 (01) : 157 - 163
  • [34] Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31
    Maryse Simoneau
    Tahar O Aboulkassim
    Hélène LaRue
    François Rousseau
    Yves Fradet
    Oncogene, 1999, 18 : 157 - 163
  • [35] A novel t(5;11)(q31;p15) involving the NUP98 gene on 11p15 is associated with a loss of the EGR1 gene on 5q31 in a patient with acute myeloid leukemia
    Wang, Yong
    Xue, Yongquan
    Chen, Suning
    Wu, Yafang
    Pan, Jinlan
    Zhang, Jun
    Shen, Juan
    CANCER GENETICS AND CYTOGENETICS, 2010, 199 (01) : 9 - 14
  • [36] Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q)
    Lai, F
    Godley, LA
    Joslin, J
    Fernald, AA
    Liu, J
    Espinosa, R
    Zhao, ND
    Pamintuan, L
    Till, BG
    Larson, RA
    Qian, ZJ
    Le Beau, MM
    GENOMICS, 2001, 71 (02) : 235 - 245
  • [37] DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
    Hahn, SA
    Schutte, M
    Hoque, ATMS
    Moskaluk, CA
    daCosta, LT
    Rozenblum, E
    Weinstein, CL
    Fischer, A
    Yeo, CJ
    Hruban, RH
    Kern, SE
    SCIENCE, 1996, 271 (5247) : 350 - 353
  • [38] Candidates for the AML tumor suppressor gene mapped to a minimal deletion interval at 5q31.
    Kravarusic, J
    Arbieva, ZH
    Xie, H
    Horrigan, SK
    Le, TT
    Westbrook, CA
    AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (04) : A133 - A133
  • [39] Primate-specific endogenous cis-antisense transcription in the human 5q31 protocadherin gene cluster
    Lipovich, L
    Vanisri, R
    Kong, SL
    Lin, CY
    Liu, ET
    JOURNAL OF MOLECULAR EVOLUTION, 2006, 62 (01) : 73 - U57
  • [40] Primate-Specific Endogenous Cis-Antisense Transcription in the Human 5q31 Protocadherin Gene Cluster
    Leonard Lipovich
    Ravi Raj Vanisri
    Say Li Kong
    Chin-Yo Lin
    Edison T. Liu
    Journal of Molecular Evolution, 2006, 62 : 73 - 88